Research programme: AAV based gene therapy - AXONIS Therapeutics
Latest Information Update: 28 Jun 2024
At a glance
- Originator AXONIS Therapeutics
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Chloride channel agonists; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Neurological disorders; Spinal cord injuries
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Epilepsy in United Kingdom (Parenteral)
- 28 Jun 2024 No recent reports of development identified for research development in Neurological-disorders in United Kingdom (Parenteral)
- 28 Jun 2024 No recent reports of development identified for research development in Spinal-cord-injuries in United Kingdom (Parenteral)